life scienc tool diagnost
reason report
revenu miss lower guid confirm uncertain
bottom line remain market perform view
compani still inadequ posit growth biolog
despit recent bioaccord launch emerg standard
biomolecular analysi close tie competitor product
competit product rapidli gain
traction drug develop head toward stronghold
qa/qc long-term deliv appear major
revenu miss end flat organ growth driven declin
instrument lead indic challeng ahead
ta instrument deliv one worst quarter declin
organ sale pharma market core
also flat asia deliv led challeng china europ
declin well industri declin organ ep
guidanc also lower
organ sale growth lower vs prior guidanc
believ challeng uniqu associ
limit read-thru peer compani appear deliv
industri averag expect link despit
deliv low-singl digit growth sciex larg due tough clinic
mass spec compar think reflect weak
across lc-m industri overal agre comparison
like get challeng overal
earlier sale forc reorgan limit posit
biomolecul grow concern us reflect
weak instrument overal sale believ instrument sale
indic challeng ahead stem sale forc
organ conduct last year believ
impact lack sale forc effect like continu
instrument sale lead indic consum pull
ahead look detail call around mass spec lc
report revenues/ep vs
 street estim organ revenu growth
flat y/i vs our/street estim soft demand
driven weaker sale china europ slow releas
key pharma industri custom budget sale asia
constant currenc eu sale declin cc also
lower guidanc organ growth
reiter expect fx impact ep guidanc
also lower
european soft concern like grow european sale
declin y/i peer compani suggest
weak europ believ investor like rais increasingli
question around europ though believ lag
pleas refer page import disclosur price chart analyst certif
overal lc-m market believ investor like view broader
european market bit softer
question call believ investor like focu
overal challeng instrument sale larg associ mass
spec impact flagship lc uptak recent
launch bioaccord expect see instrument
gain traction biopharma qa/qc continu build
manag bench retir key leadership last
year includ recent retir ta instrument terri kelli
challeng europ china
dollar thousand except ep
interest/ expens
revenu bp
compani report svb leerink estim
puneet souda certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori water corpor
leerink place market perform rate januari
creat bluematrix
pt reflect ev/ebitda multipl line ev/ebitda lst multipl
share current trade alreadi tool averag believ would
warrant higher multipl recent appoint sale rep reach full product help drive lc-m growth
biopharma market still believ offer premium product potenti return growth
sale rep new mass spec product challeng launch bio-tof address meet biotherapeut
need market deriv price target appli averag ev/ebitda multipl compris
life scienc peer group
risk valuat
primari risk price target includ
could acceler stock repurchas help drive stock higher one could also envis biopharma
uptick drive equival revenu growth across competitor uptick biopharmaceut fund
could pose risk know market remain healthi
fda approv process directli impact biopharma biotech compani could continu favor
older method continu domin biopharma drug sale could continu acceler result
acceler spend current level revenu deriv biopharma
uptick spend biopharma like increas revenu
acceler global budget research could caus upsid risk forecast expand budget
govern academ fund could result higher revenu rel estim
signific academ exposur revenu ww nih exposur less revenu pickup
academ spend could headwind rate estim increas global budget could
result shift focu strategi growth could increas oper risk
emerg market pose signific upsid risk view despit signific growth china far
acceler uptak product could impact view sudden macroeconom chang lead increas
fund fund could impact posit china repres compani revenu
chang regul lead easier oper china foreign compani like benefit well
given posit market
high attach rate integr part busi model despit entri high resolut mass
spec lc could continu remain demand drive sale higher estim could continu
maintain legaci high attach rate lc system due requir technolog competit
chang market
fda regul remain paramount affect adopt rate clinic diagnost tool clinic
diagnost remain major growth area futur chang regul restrict use mass
spectromet clinic diagnost laboratori could also improv compani prospect restrict could
affect growth adopt rate certain tool regul would also increas cost complianc test
rate price target histori danah corpor
leerink initi coverag outperform rate septemb
creat bluematrix
coverag suspend longer put forth statement valuat
risk valuat
set forth valuat statement risk valuat
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
